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Abstract G protein-coupled receptor kinase 2 (GRK2) phos-
phorylates G protein-coupled receptors resulting in uncoupling
from G proteins. Receptors modulate GRK2 expression, however
the mechanistic basis for this effect is largely unknown. Here we
report a novel mechanism by which receptors use the extra-
cellular signal-regulated kinase (ERK) cascade to regulate
GRK2 cellular levels. ERK activation by receptor stimulation
elevated endogenous GRK2 while antagonist treatment decreased
cellular GRK2. Activating ERK by overexpressing constitutive
active MEK-1 or Ras elevated GRK2 protein levels while
blocking ERK using PD98059 or dominant negative Ras
abolished this effect. These data suggest ERK is a critical
regulator of GRK2 levels. ß 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
Key words: G protein-coupled receptor;
Receptor desensitisation; Angiotensin II;
Mitogen activated kinase; Signal transduction
1. Introduction
G protein-coupled receptors activate multiple molecules
including G proteins and the extracellular signal-regulated
kinase (ERK)/mitogen-activated protein kinase cascade. A
family of G protein receptor kinases (GRKs) rapidly
phosphorylate and together with L-arrestin desensitise G pro-
tein signalling following agonist occupation [1]. GRK2 is a
ubiquitous member of this serine/threonine kinase family
[2,3]. The phosphorylated receptors are recognised by cyto-
solic arrestin proteins that uncouple receptors from G pro-
teins thereby terminating G protein signalling [4]. However,
GRK2 and arrestin can also turn on signalling via ERK cas-
cade activation. Arrestin-tagged receptors recruit other mole-
cules including Src kinase to the receptor. This serves to target
the receptors for endocytosis (sequestration) through clathrin-
coated pits, a process that initiates ERK signalling by several
receptors [5]. GRK2-mediated phosphorylation of activated
receptors thus plays a critical role in regulating activity and
surface expression of G protein-coupled receptors [2,6,7]. In
addition, GRK2 regulates the activity of other signalling pro-
teins including GKq, phosducin and cytoskeletal proteins
[3,8,9].
GRK2 activity is regulated by a plethora of signalling mol-
ecules such as receptors, GLQ, lipids, c-Src kinase, protein ki-
nase C and A, calmodulin and ERK [2,7,10]. Within seconds
to minutes following receptor activation these proteins regu-
late GRK2 activity, however, we have little information about
the mechanistic basis for regulation of GRK2 cellular levels.
Receptor activity is an important regulator of GRK2 ex-
pression [6,11]. In cardiac myocytes, prolonged agonist stim-
ulation (hours) of L-adrenergic receptors induces GRK2 ex-
pression while antagonist treatment reduces GRK2 levels [12].
Moreover, recent data suggest that dysregulated GRK2 ex-
pression may play a role in the pathophysiology of human
diseases such as heart hypertrophy and failure, hypertension
and chronic in£ammation [13,14]. These results imply that
receptors generate a signal that controls GRK2 expression.
We herein describe a series of experiments that show ERK
activation is required for receptor-mediated changes in GRK2
expression. These data enhance our understanding of the reg-
ulatory mechanisms controlling receptor signalling.
2. Materials and methods
2.1. Materials
Cell culture media and additions were from Life Technologies or
Sigma. Hormones and other reagents were purchased from Sigma.
The secondary antibodies, ECL reagent and hyper¢lms were from
Amersham. The AT1 antagonist losartan was a gift from Gaethan
Thibault (University of Montreal, QC, Canada). Antibodies against
GRK2 were from Upstate (clone C5/1.1) or Santa Cruz Biotechnol-
ogy (C-15, cat # sc-562). Total ERK-, phospho-ERK-antibodies and
PD98059 were obtained from New England Biolabs.
2.2. DNA
Julian Downward (Imperial Cancer Research Fund, London, UK)
generously provided plasmid encoding RasV12, Raymond Erickson
(Harvard, MA, USA) kindly supplied MEK-DD encoding plasmid,
while speci¢c antibodies against Ras was generously provided by
Berthe Willumsen (University of Copenhagen).
2.3. Cell culture and transfection
Ventricular myocyte-enriched cultures were prepared from cardiac
ventricles of neonatal Wistar rat pups by trypsin digestion and me-
chanical disruption as described [15]. Cardiomyocytes were dissoci-
ated using 1 mg/ml trypsin and 20Wg/ml DNase in a 20.1 mM HEPES
bu¡er (pH 7.4). The cells were plated (approx. 5U104 cells/cm2) in
minimal essential medium (MEM) supplemented with 5% (v/v) foetal
calf serum. On day 3 after preparation, the medium was changed to
serum-free MEM, and di¡erent compounds were added. On day 4 or
5, cells were processed for immunoprecipitation and Western blotting.
Cos-7 cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% (v/v) foetal calf serum, 10 Wg/ml non-essential
amino acids and 0.1 Wg/ml gentamycin. Transient transfections were
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performed using a DEAE^dextran/adenovirus method as described
[16].
2.4. Adenoviral infection
Adenoviral infection was achieved using an E1-de¢cient type 5 ad-
enoviral containing a GRK2 encoding gene. On day 2, the cells were
incubated with virus for 15 min before adding back culture medium.
Two adenoviral transgenes were employed; empty vector (Ad5) and
a GRK2 containing virus produced in this laboratory using the
pAdEasy and pAdTrack from Stratagene.
2.5. Immunoprecipitation and western blot analysis
Cells were lysed in 1.0% Triton X-100, 50 mM Tris^HCl, pH 7.5,
containing in addition 100 mM NaCl, 5 mM EDTA, 10 Wg/ml Leu-
peptin, 10 Wg/ml Aprotinin, 1 mM PMSF, and 1 mM Na3VO4 as
described [17]. After centrifugation (12 000Ug, 10 min), cellular ex-
tracts were immunoprecipitated using GRK2-speci¢c antibodies fol-
lowed by incubation with protein A^Sepharose for 2 h at 4‡C. Im-
munoprecipitates were washed three times with ice-cold 50 mM Tris^
HCl bu¡er, pH 7.5, containing 100 mM NaCl, 0,1% Triton X-100 and
the aforementioned protease inhibitors. Proteins were resolved by
SDS^polyacrylamide gel electrophoresis (PAGE) and transferred to
polyvinylidene di£uoride (PVDF) membranes to be probed with the
appropriate antibodies in TBS containing 5% milk, 0,2% Tween 20
(Merck) and 0.02% NaN3. PVDF membranes were incubated for 2 h
at room temperature with the primary antibodies, washed four times
in TBS with 0.2% Tween 20, and probed with horseradish peroxidase-
conjugated secondary antibodies (Amersham). Blots were developed
using the ECL reagent and exposed to Hyper¢lm (Amersham). Band
density was quanti¢ed using laser densitometric analysis.
2.6. Inositol phosphate accumulation
Cells were labelled overnight with 2 WCi [3H]inositol/ml in inositol-
free media. Cells were preincubated in PBS with 10 mM LiCl, 1 mM
MgCl2 and 90 WM CaCl2; before agonist stimulation for 20 min at
37‡C. Inositol phosphates were extracted using 20 mM formic acid
and loaded on Evergreen columns, 3 ml, 1 g/ml AG 1U8 resin (Bio-
Rad). The columns were washed with 40 mM ammonium hydroxide,
pH 9, followed by elution using 2 M ammonium format, 0.1 M formic
acid into 4 ml Ultima-Flo scintillation liquid (Packard).
3. Results
3.1. AT1 activity regulates GRK2 expression
We ¢rst validated two GRK2 antibodies for their ability to
detect GRK2 in our experimental system. Used directly for
immunoblotting both antibodies detected a 80 kDa band in
myocyte and Cos-7 cell lysate corresponding to the GRK2
protein standard obtained from Cos-7 cells infected with
GRK2-adenovirus (Fig. 1A). Since myocytes contained less
GRK2 protein than Cos-7 cells, we immunoprecipitated
GRK2 from myocyte lysates before SDS^PAGE. This proce-
dure yielded a stronger GRK2 band (Fig. 1A), and therefore
this procedure was employed for further studies. In control
experiments, immunoprecipitated GRK2 increased in a linear
fashion as a function of increasing amounts of cardiomyocyte
lysate (Fig. 1B), and blocking the antibody with peptide anti-
gen abolished the 80 kDa band (not shown). We next exam-
ined if AT1 activation would e¡ect GRK2 expression. Activa-
tion of recombinantly expressed AT1 in Cos-7 increased
GRK2 protein after 2 h, and GRK2 remained increased for
at least 24 h (Fig. 1C). The AT1 stimulation caused a long-
lasting ERK phosphorylation without changing ERK expres-
sion (Fig. 1C). In addition, activation of native AT1 in car-
diomyocytes elevated GRK2 expression (Fig. 1D) with a sim-
ilar time course (not shown). This e¡ect that was blocked by
the AT1 antagonist losartan suggesting GRK2 expression re-
£ects AT1 activity (Fig. 1D). These results were con¢rmed
with both GRK2 antibodies.
3.2. ERK1 and ERK2 inhibition down-regulate GRK2
Since ERK phosphorylates GRK2 [18], we speculated the
ERK cascade could play a role in regulation of GRK2 ex-
pression. Two di¡erent experiments showed ERK inhibition
decreased GRK2 levels. First, PD98059, a pharmacological
MEK-1 inhibitor prominently decreased GRK2 levels, sug-
gesting ERK activation is required for GRK2 expression in
both cardiomyocytes and Cos-7 cells (Fig. 2A,B). Interest-
ingly, the most prominent PD98059 e¡ect was a reduction
in GRK expression in an agonist-independent manner. In
Fig. 1. GRK2 expression in cardiomyocytes and Cos-7 cells.
A: (lanes 1^4) GRK2 Western blot obtained using anti-GRK2 anti-
bodies from Upstate (U) or Santa Cruz (S). Equal amounts of cellu-
lar protein (70 Wg) were subjected to SDS^PAGE. A: (lanes 5 and
6) GRK2 Western blot of lysate (20 Wg protein) from Cos-7 cells in-
fected with empty vector adenovirus (lane 5) or GRK2 containing
virus (lane 6). A: (lane 7 and 8) Cell lysates were immunoprecipi-
tated (IP) and electrophoresed before GRK2 Western blotting.
B: GRK2 levels increase as a function of the amounts of cellular
protein. Data are representative of three experiments. C: IP and
Western blot of GRK2 protein from Cos-7 cells as a function of
time in the presence and absence of 100 nM AngII. Samples were
normalised for protein content. Western blots for total ERK
(T-ERK) serve as loading controls while blots for phospho-ERK
(P-ERK) indicate ERK activation. Data are representative of four
experiments. D: GRK2 IP and Western blot in the presence or ab-
sence of 100 nM AngII or losartan for 24 h in serum-free medium.
Histograms are densitometric quanti¢cation of scanned GRK2 im-
munoblots of lysates treated as indicated. Results are the means
þ S.E.M. of double determinations from four experiments and were
analysed by Student’s t-test. *P6 0.01 for AngII versus control,
#P6 0.01 for losartan+AngII versus AngII.
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control experiments PD98059 blocked ERK activation with-
out changing ERK expression (Fig. 2A,B). Secondly, transient
overexpression of dominant negative RasT17N (veri¢ed by
Western blotting) prevented the angiotensin II (AngII) e¡ect
on GRK2 expression (Fig. 2B). We infer from these data that
ERK activation is required for control of GRK2 expression in
cultured cardiomyocytes.
3.3. Other receptors up-regulate GRK2 through ERK activation
To examine whether ERK activity serves as a general signal
for regulation of GRK2 expression in cardiomyocytes, we
analysed the e¡ects of activating two other receptors; K1-ad-
renergic receptors (a G protein-coupled receptor), and EGF
receptors that belong to the tyrosine kinase family of recep-
tors. Agonist stimulation of both receptors elevated GRK2
expression by a mechanism that required ERK activation,
since their GRK2 response was blocked by PD98059 (Fig.
3A).
3.4. Constitutively active Ras and MEK-1 up-regulate GRK2
We examined if ERK activation by overexpression of con-
stitutively active upstream activators in the ERK cascade
would a¡ect GRK2 expression. Indeed, overexpression (veri-
¢ed by Western blotting) of RasV12 and MEK-DD protein
elevated GRK2 levels while ERK expression remained un-
changed in Cos-7 cells (Fig. 3B). The RasV12 response was
speci¢c for ERK activation since PD98059 completely pre-
vented the GRK2 induction by RasV12. Taken together these
experiments show that ERK activation is both necessary and
su⁄cient for elevation of GRK2 in cardiomyocytes and Cos-7
cells.
3.5. GRK2 down-regulation enhanced AT1 signalling
To begin to analyse if GRK2 down-regulation a¡ects AT1
signalling, we measured the accumulation of inositol phos-
phates after GRK2 down-regulation by PD98059. In both
Fig. 2. ERK/mitogen-activated protein kinase blockade reduces
GRK2 expression. A: Cardiac myocytes were treated with the
MEK-1 inhibitor PD98059 with and without 100 nM AngII for
24 h in serum-free medium. Cell lysates were immunoprecipitated
with antibodies against GRK2, ERK or phospho-ERK and Western
blots prepared. Histograms are densitometric quanti¢cation of
scanned immunoblots representative of four independent experi-
ments. *P6 0.01. B: The AT1 was recombinantly expressed with or
without co-expression of RasT17N in Cos-7 cells. Histograms are
densitometric quanti¢cation of scanned GRK2 immunoblots. Ex-
pression of RasT17 was con¢rmed by immunoblotting using an
antibody against Ras. Results are the means þ S.E.M. of double de-
terminations from three to six experiments. *P6 0.01 for AngII ver-
sus control, #P6 0.05 for # versus AngII.
Fig. 3. ERK activation controls GRK2 expression. A: GRK2, total
ERK and phospho-ERK immunoblots of lysates from cardiomyo-
cytes treated with epidermal growth factor (EGF) and phenyl-
ephrine (PE) for 24 h. The GRK2 expression was quanti¢ed by den-
sitometric analysis of Western blots using anti-GRK2 antibodies.
Data are the means þ S.E.M. of double determinations from four to
¢ve experiments. *P6 0.1, #P6 0.01. B: Quanti¢cation of scanned
GRK2 immunoblots from transiently transfected Cos-7 cells in the
presence and absence of constitutively activated up-stream MAP ki-
nase partners RasV12 and MEK-DD and PD98059. T-ERK, MEK-
DD and RasV12 immunoblots are shown. Results are the means
þ S.E.M. of double determinations from three experiments.
*P6 0.1, #P6 0.01 for RasV12+PD98059 versus RasV12.
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cell systems, this treatment increased inositol phosphate accu-
mulation in response to AT1 activation, suggesting the de-
creased GRK2 levels reduce receptor desensitisation, Fig. 4.
4. Discussion
Cells receive inputs from many di¡erent surface receptors at
the same time and must interpret and integrate them in the
context of each other. GRK2 plays a key role in this process;
it has multiple di¡erent receptor substrates and regulation of
cellular GRK2 levels represents a way to control signalling
through G protein-coupled receptors [6,7]. However, we
have little knowledge of the molecular mechanisms involved
in such a regulation. We provide evidence that prolonged AT1
activation in cardiomyocytes increase the cellular complement
of GRK2 while the AT1 antagonist losartan reduces this pa-
rameter. These data are in line with previous reports. Thus,
increased GRK2 expression was observed in mitogen-acti-
vated lymphocytes, in mouse hearts following treatment
with L-adrenergic agonists or pressure-induced hypertrophy,
and in transgenic mice with cardiac overexpression of L-ad-
renergic receptors [12,19,20].
We hypothesised receptors generate speci¢c signals that in-
crease GRK2 expression, and present a series of experiments
showing ERK activation may represent such a signal. This
inference is based on four di¡erent experiments. First, the
ERK pathway blocker PD98059 abolished the GRK2 induc-
tion by AT1 stimulation in cultured cardiomyocytes. Interest-
ingly, the tyrosine kinase c-Src also regulates GRK2 expres-
sion. Accordingly, Src-mediated phosphorylation of GRK2
increases its degradation through the proteasome pathway
[7,11]. Taken together with our observations, we speculate
that c-Src and ERK exert a di¡erential regulation on GRK2
expression. Thus, c-Src decreases GRK2 expression while
ERK activation increases GRK2 levels.
Secondly, the ERK-dependent regulation of GRK2 expres-
sion could be extended to other cell lines, since blocking ERK
activation down-regulated GRK2 in Cos-7 cells expressing
recombinant AT1 receptors. In addition, overexpression of
dominant negative RasT17N, an alternative way of preventing
ERK activation, blocked the AngII e¡ect on GRK2 expres-
sion, con¢rming the notion that ERK activation is required
for regulation of GRK2 expression. This suggests the result
may represent a biologically signi¢cant and general mecha-
nism.
Thirdly, the link between ERK activation and GRK2 ex-
pression is shared by other endogenous receptors in cardio-
myocytes. The K1-adrenergic and the EGF receptors also use
ERK to regulate GRK2 expression, since PD98059 abolished
the elevation in GRK2 expression produced by these recep-
tors. If other RTKs also regulate GRK2 expression through
ERK activation, this might represent a novel type of desensi-
tisation involving receptor cross-talk by which excessive RTK
activity elevates GRK2 expression leading to decreased G
protein-coupled receptor signalling.
Fourthly, if the inference that ERK regulates cellular
GRK2 levels is correct, any way of increasing ERK activity
should elicit the e¡ect. This prediction was ful¢led since acti-
vating ERK using constitutively active Ras and MEK-1 ele-
vated GRK2 expression in Cos-7 cells. It is striking that the
ERK cascade regulates GRK2 expression, since ERK is acti-
vated by very diverse stimuli including G protein-coupled re-
ceptors, receptor tyrosine kinases, integrins, ion channels and
mechanical stretch receptors [21,22]. It is tempting to specu-
late that ERK activation by these molecules is linked to
GRK2 expression suggesting cells have evolved a way of ad-
justing receptor signalling to the general level of cell signalling
by multiple proteins.
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